Virtual Library

Start Your Search

  • WCLC 2016

    17th World Conference on Lung Cancer

    Access to all presentations that occur during the 17th World Conference on Lung Cancer in Vienna, Austria

    Presentation Date(s):  
    • Dec 4 - 7, 2016
    • Total Presentations: 2466

    To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.

    Presentations will be available 24 hours after their live presentation time

Filter Results:

Show Only Available Presentations

  • +

    OA03 - Immunotherapy Checkpoint Inhibitors in Advanced NSCLC

    • Type: Oral Session
    • Track: Chemotherapy/Targeted Therapy/Immunotherapy
    • Presentations: 8
    • Moderators:L. Crinò
    • Coordinates: 12/05/2016, 11:00 - 12:30, Hall C8
    • +

      OA03.07 - KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab 

      12:05 - 12:15  |  Author(s): R. Herbst

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    MA07 - ALK-ROS1 in Advanced NSCLC

    • Type: Mini Oral Session
    • Track: Advanced NSCLC
    • Presentations: 12
    • Moderators:N. Singh
    • Coordinates: 12/06/2016, 11:00 - 12:30, Lehar 1-2
    • +

      MA07.01 - Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK+ NSCLC

      11:00 - 11:06  |  Author(s): S. Ignatius Ou

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      MA07.02 - Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer

      11:06 - 11:12  |  Author(s): D..R. Camidge

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    MA08 - Treatment Monitoring in Advanced NSCLC

    • Type: Mini Oral Session
    • Track: Advanced NSCLC
    • Presentations: 12
    • Moderators:R. Perez-Soler
    • Coordinates: 12/06/2016, 11:00 - 12:30, Lehar 3-4
    • +

      MA08.01 - A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma

      11:00 - 11:06  |  Author(s): H. Wakelee

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    MA09 - Immunotherapy Combinations

    • Type: Mini Oral Session
    • Track: Chemotherapy/Targeted Therapy/Immunotherapy
    • Presentations: 12
    • Moderators:M. Sebastian
    • Coordinates: 12/06/2016, 14:20 - 15:50, Strauss 2
    • +

      MA09.02 - Pembrolizumab + Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non–Small Cell Lung Cancer: KEYNOTE-021 Cohort G

      14:26 - 14:32  |  Author(s): C. Langer

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    P2.06 - Poster Session with Presenters Present

    • Type: Poster Presenters Present
    • Track: Scientific Co-Operation/Research Groups (Clinical Trials in Progress should be submitted in this category)
    • Presentations: 47
    • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
    • +

      P2.06-014 - Phase 2 Study of Glesatinib or Sitravatinib with Nivolumab in Non-Small Cell Lung Cancer (NSCLC) after Checkpoint Inhibitor Therapy

      14:30 - 14:30  |  Author(s): J. Nemunaitis

      • Abstract
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    PL04a - Plenary Session: Immune Checkpoint Inhibitors in Advanced NSCLC

    • Type: Plenary
    • Track: Chemotherapy/Targeted Therapy/Immunotherapy
    • Presentations: 5
    • Moderators:J. Soria
    • Coordinates: 12/07/2016, 08:45 - 09:40, Hall D (Plenary Hall)
    • +

      PL04a.02 - OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses (Abstract under Embargo until December 7, 7:00 CET)

      08:55 - 09:05  |  Author(s): S.M. Gadgeel

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    PR04 - Press Conference: Advanced Care

    • Type: Press Conference
    • Track:
    • Presentations: 5
    • Moderators:C. Zielinski
    • Coordinates: 12/07/2016, 10:30 - 11:45, Schubert 1
    • +

      PR04.02 - OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses

      10:30 - 10:30  |  Author(s): S.M. Gadgeel

      • Abstract
      • Presentation
      • Slides

      No abstract available for this presentation

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    OA23 - EGFR Targeted Therapies in Advanced NSCLC

    • Type: Oral Session
    • Track: Advanced NSCLC
    • Presentations: 8
    • Moderators:O.T. Brustugun
    • Coordinates: 12/07/2016, 14:20 - 15:50, Stolz 2
    • +

      OA23.03 - Second-Line Afatinib for Advanced Squamous Cell Carcinoma of the Lung: Analysis of Afatinib Long-Term Responders in the Phase III LUX-Lung 8 Trial

      14:40 - 14:50  |  Author(s): G. Goss

      • Abstract
      • Presentation
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    P3.02a - Poster Session with Presenters Present

    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 37
    • Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
    • +

      P3.02a-016 - Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non-Small-Cell Lung Cancer (NSCLC)

      14:30 - 14:30  |  Author(s): J.C. Yang

      • Abstract
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

  • +

    P3.02b - Poster Session with Presenters Present

    • Type: Poster Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 126
    • Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
    • +

      P3.02b-003 - Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumour and Serum Biomarkers

      14:30 - 14:30  |  Author(s): E. Felip

      • Abstract
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      P3.02b-103 - Identification of On-Target Mechanisms of Resistance to EGFR Inhibitors Using ctDNA Next-Generation Sequencing

      14:30 - 14:30  |  Author(s): J.J. Lin

      • Abstract
      • Slides

      Loading...

      IASLC Members: To view this content or have the option to purchase this event, click here to login.
      Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.

    • +

      P3.02b-115 - Clinical Activity of Osimertinib in EGFR Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib

      14:30 - 14:30  |  Author(s): S.M. Gadgeel

      • Abstract

      Loading...